Bladder Cancer Diagnosis, Therapeutics, and Management

Improving Bladder Cancer Staging.- Approaches to Carcinoma In Situ (CIS).- Fluorescence Cytoscopy.- Restaging TURBT.- Understaging T2: Limitations of Pelvic Imaging.- MRI Endorectal Coil.- PET Imaging: Advances in the Detection of Locally Advanced and Nodal Disease.- Detection of Extravesical Disease: A Lack of Bladder Cancer Markers.- Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI.- Presence and Significance of Micrometastases.- Optimizing Treatment of Localized Disease.- Perioperative Intravesical Therapy.- BCG Refractory Disease.- Beyond BCG: Gemcitabine.- Beyond BCG: Taxanes.- Extended Lymph Node Dissection.- Prostate Capsule Sparing Cystectomy.- Preservation of Reproductive Organs in Women.- Nerve Sparing Radical Cystectomy.- Quality of Care Indicators for Radical Cystectomy.- Continent Diversion: QOL of Orthotopic Diversion vs. Ileal Conduit.- Voiding Dysfunction After Orthotopic Diversion.- Overcoming the Stigma of Complications of Continent Cutaneous Diversion.- Locally Advanced / Distant Disease: Multi-Modality Treatment.- Neoadjuvant Chemotherapy: The New Standard.- Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Where’s the Proof?.- Beyond MVAC: New and Improved Chemotherapeutics.- Next Steps: Translational Research.- The Role of Microarray Technologies in Bladder Cancer Management.- Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies.- Tools for Study: National Databanking.- Vaccine Development.- Advances in Gene Therapy for Bladder Cancer.